Akira Kurokawa President and CEO Kazuo Koshiji Senior Corporate, CFO Head of Finance & Administration Division Naveed Shams, M.D., Ph.D. Senior Corporate Officer, CSO Head of Global Research & Development PLAY LIST from the beginning Investor Meeting on Q3 FY2017 Results Today’s Agenda Q3 FY2017 Financial Results ended December 31, 2017 Santen’s Values Q3 FY2017 Financial Results ended December 31, 2017 To Become a Specialized Pharmaceutical Company with a Global Presence Q3 FY2017 Financial Highlights Q3 FY2017 Revenue Q3 FY2017 Core Operating Profit Performance by Business (Japan) Performance by Business (Asia) Performance by Business (EMEA) FY2017 P&L Forecast FY2017 Dividend Forecast (No change from May 10) About DE-109 Filing Process Status of Research & Development Q3 FY2017 Pipeline / Product Development Status (1) Pipeline / Product Development Status (2) Summary of Q3 FY17 Announcement Summary of Q3 FY17 Announcement Reference Q3 FY2017 Profit / Loss Q3 FY2017 Financial Position Q3 FY2017 Segment Revenue Capital Expenditures / Depreciation & Amortization Prescription Ophthalmic Market in Japan DE-117 Forward-Looking Statements @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Back Next